Cargando…
Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer
IMPORTANCE: Mortality, morbidity, and health-related quality of life (HRQoL) are patient-relevant end points generally considered in the early benefit assessments of new cancer treatments. Progression-related end points, such as time to progression or progression-free survival, are not included, alt...
Autores principales: | Marschner, Norbert, Zacharias, Stefan, Lordick, Florian, Hegewisch-Becker, Susanna, Martens, Uwe, Welt, Anja, Hagen, Volker, Gleiber, Wolfgang, Bohnet, Sabine, Kruggel, Lisa, Dille, Stephanie, Nusch, Arnd, Dörfel, Steffen, Decker, Thomas, Jänicke, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064873/ https://www.ncbi.nlm.nih.gov/pubmed/32154886 http://dx.doi.org/10.1001/jamanetworkopen.2020.0643 |
Ejemplares similares
-
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study
por: Dörfel, Steffen, et al.
Publicado: (2017) -
Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project
por: Marschner, Norbert, et al.
Publicado: (2019) -
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL
por: Thill, M., et al.
Publicado: (2023) -
Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
por: Hegewisch‐Becker, Susanna, et al.
Publicado: (2018) -
Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial
por: Welt, A., et al.
Publicado: (2016)